Hoth Therapeutics(HOTH) - 2020 Q2 - Quarterly Report

Commission File Number: 001-38803 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Hoth Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 82-1 ...